Mayo Clinic taps Gianrico Farrugia as new CEO, president

The Mayo Clinic has named Gianrico Farrugia, MD, as its new president and CEO, the organization announced Friday. The board of trustees elected Farrugia, who was formerly vice president, to succeed John Noseworth, MD, who will remain in his position until his retirement at the end of the year.

The Mayo Clinic is a nonprofit organization that cares for more than 1.3 million patients annually, with more than 68,000 staff members and a revenue of nearly $12 billion.

Farrugia has been vice president of Mayo Clinic and CEO of Mayo Clinic in Florida in January 2015, where he led more than 6,400 staff members. He has spent 30 years as a Mayo physician. Prior to serving as vice president, he was director of Mayo Clinic’s Center for Individualized Medicine. He was also the co-founder of the Center for Innovation at Mayo Clinic.

“Dr. Farrugia is a visionary and servant leader who brings with him a wealth of experience and knowledge─both as an innovator and an executive,” Noseworthy said in a statement. “In partnership with our staff across Mayo Clinic, and with a deep commitment to our values and mission, he will affirm Mayo Clinic’s position as the global health care leader for generations to come."

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.